V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240001922 | 240011848 | 1.7 | 57.7 | Curative (C) | 2018-12-26 | 2020-04-09 | null | N | null | CYTARABINE + DAUNORUBICIN | 101630483 |
| 240001939 | 240011849 | 1.85 | 29.6 | Curative (C) | 2022-04-28 | 2022-05-06 | Trial Unspecified | 01 | N | BENDAMUSTINE + OBINUTUZUMAB | 100741940 |
| 240002062 | 240011851 | 1.85 | 54.9 | 03 | 2022-03-27 | 2022-04-10 | Venetoclax | 02 | N | PEG INTERFERON | 101172936 |
| 240002063 | 240011852 | 1.71 | 104.4 | Curative (C) | 2019-01-15 | 2019-01-15 | Lenalidomide 25mg (Cycle 1 to 25) | 02 | null | TRANSPLANT CYCLOPHOSPHAMIDE + FLUDARABINE (+/- TBI) | 100752132 |
| 240002093 | 240011853 | 1.58 | 68 | Palliative (P) | 2018-01-23 | 2018-01-23 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | N | LCHIV IC-2 | 100488667 |
| 240002171 | 240011854 | 1.82 | 73.9 | Disease modification (D) | 2021-12-17 | 2021-12-21 | R IVAC | 02 | null | IMATINIB | 101783614 |
| 240002241 | 240011855 | null | 90.6 | null | 2020-11-27 | 2020-11-27 | IVAC | 02 | null | AML MYECHILD 01 HD ARAC | 100540022 |
| 240002248 | 240011856 | 1.74 | 79 | Curative (C) | 2018-02-21 | 2018-02-21 | GDP | 01 | N | VENETOCLAX | 100581147 |
| 240002287 | 240011858 | 1.66 | 91.4 | 03 | 2018-09-09 | 2018-09-16 | Venetoclax | 02 | null | METHOTREXATE INTRATHECAL | 101567333 |
| 240002374 | 240011859 | 1.68 | 72.5 | null | 2020-08-03 | 2020-09-21 | Venetoclax | 02 | null | ALL ALLR3: S/IR IND | 100187681 |
| 240002391 | 240011860 | 1.65 | 71.1 | null | 2021-07-13 | 2021-07-17 | R CODOX M | N | null | AZACITIDINE + VENETOCLAX | 101179262 |
| 240002489 | 240011862 | 0 | 71.6 | Palliative (P) | null | 2021-12-24 | null | null | N | RUXOLITINIB | 101869442 |
| 240002577 | 240011863 | 1.74 | 83.1 | null | null | 2021-09-21 | PEG INTERFERON | null | null | CYTARABINE + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 101309020 |
| 240002610 | 240011864 | 1.7 | 76.3 | Curative (C) | 2020-02-10 | 2020-02-13 | null | 02 | null | INTERFERON ALFA | 100238819 |
| 240002619 | 240011865 | 1.6 | 56 | null | 2020-04-13 | 2020-05-03 | IBRUTINIB | 02 | null | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 101456528 |
| 240002722 | 240011867 | 1.78 | 60.2 | Disease modification (D) | 2018-11-28 | 2019-02-08 | null | 01 | N | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 100415407 |
| 240002815 | 240011869 | 1.62 | 94 | null | 2021-11-27 | 2021-11-29 | ALL UKALL2011 Maintenance A1 | N | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 100137843 |
| 240002845 | 240011870 | 0 | 79.1 | Curative (C) | 2020-08-20 | 2020-09-02 | Midostaurin | 02 | null | VINBLASTINE | 101713235 |
| 240000533 | 240011872 | 1.82 | 67.3 | null | 2020-01-02 | 2020-01-30 | GEMTUZUMAB OZOGAMICIN | N | null | ANTI-THYMOCYTE GLOBULIN + BUSULFAN + FLUDARABINE | 100823555 |
| 240000785 | 240011889 | null | null | null | null | 2018-08-19 | null | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100561983 |
| 240000892 | 240011904 | null | null | null | null | 2019-05-07 | CHOP R - 21 days | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101841918 |
| 240000911 | 240011910 | 1.74 | 61 | Curative (C) | null | 2022-02-13 | null | null | N | CYTARABINE | 100668071 |
| 240000914 | 240011912 | 1.54 | 59 | null | null | 2018-05-30 | null | null | null | AML18 TRIAL | 100619343 |
| 240000921 | 240011913 | 1.7 | 75.35 | null | 2021-10-03 | 2022-03-04 | Rituximab | 02 | null | RITUXIMAB | 100958443 |
| 240000922 | 240011914 | 1.64 | 69 | 03 | null | null | null | null | N | TRIAL UNSPECIFIED | 100060122 |
| 240000984 | 240011918 | 1.66 | 53.6 | null | null | 2021-12-04 | null | N | null | AML19 TRIAL | 101342003 |
| 240001095 | 240011921 | 1.67 | 79.4 | Palliative (P) | 2021-01-18 | 2021-02-02 | CARFILZOMIB | 02 | N | CYTARABINE HIGH DOSE | 101404275 |
| 240001895 | 240011925 | 1.61 | 77.75 | Curative (C) | null | null | IBRUTINIB | null | N | THALIDOMIDE | 100246995 |
| 240001922 | 240011926 | null | 85.5 | null | 2020-04-25 | 2020-04-26 | FLAG + Idarubicin | 02 | null | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 101630483 |
| 240002171 | 240011931 | 1.64 | 84 | Curative (C) | 2021-11-28 | 2022-02-04 | IMATINIB | 02 | N | CYTARABINE + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 101783614 |
| 240002248 | 240011933 | 1.68 | 68.8 | null | 2018-03-21 | 2018-03-22 | Niraparib | 02 | null | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 100581147 |
| 240002282 | 240011934 | 0 | 25.05 | null | 2020-01-03 | 2020-01-06 | GEMTUZUMAB OZOGAMICIN | 02 | null | PEG INTERFERON | 101256721 |
| 240002287 | 240011935 | 1.63 | 60.9 | Curative (C) | 2018-08-24 | 2018-10-09 | Melphalan IV High dose | 01 | null | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 101567333 |
| 240002374 | 240011936 | 1.8 | 83 | Curative (C) | null | 2020-09-26 | AML16 DA 3+10 | null | N | PEG INTERFERON | 100187681 |
| 240002391 | 240011937 | 1.51 | 70.6 | null | 2021-06-13 | 2021-07-17 | ALEMTUZUMAB + FLUDARABINE + LEAM | 02 | null | CYTARABINE + FLUDARABINE + IDARUBICIN | 101179262 |
| 240002489 | 240011939 | 1.79 | 16.4 | Curative (C) | null | 2022-02-09 | null | null | N | AML INTERIM GUIDELINES FLAG-IDA | 101869442 |
| 240002577 | 240011940 | 1.81 | 76.4 | Curative (C) | 2021-10-13 | 2021-10-17 | null | 02 | N | INTERFERON ALFA | 101309020 |
| 240002619 | 240011941 | 1.7 | 9.95 | Adjuvant (A) | 2020-05-03 | 2020-05-08 | Methotrexate intrathecal | 02 | null | PEG INTERFERON | 101456528 |
| 240002722 | 240011943 | 1.76 | 55 | null | 2019-07-05 | 2019-07-05 | Venetoclax | 02 | null | VENETOCLAX | 100415407 |
| 240002815 | 240011945 | null | 64 | Curative (C) | 2020-03-25 | 2021-11-29 | PERTUZUMAB + TRASTUZUMAB | 01 | N | MELPHALAN | 100137843 |
| 240000533 | 240011948 | null | 73.9 | Curative (C) | 2019-11-19 | 2020-01-18 | R IVAC | 02 | N | CARBOPLATIN + VINCRISTINE | 100823555 |
| 240000626 | 240011949 | 1.76 | 18.5 | null | 2017-12-31 | 2017-12-31 | CYTARABINE + DAUNORUBICIN + Gemtuzumab Ozogamicin | Y | null | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 101019381 |
| 240000792 | 240011966 | null | null | Adjuvant (A) | null | null | CHOP R | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100664186 |
| 240000800 | 240011968 | null | null | null | null | 2018-09-06 | null | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101478560 |
| 240000856 | 240011973 | null | null | null | null | 2017-04-06 | CHOP R - 21 days | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101506096 |
| 240000899 | 240011979 | 1.63 | 64.6 | Adjuvant (A) | null | 2019-06-15 | null | N | N | RITUXIMAB | 101010158 |
| 240000906 | 240011980 | 1.79 | 67.3 | Curative (C) | null | 2021-06-03 | null | 02 | N | METHOTREXATE | 101359772 |
| 240000907 | 240011981 | 1.6 | 104.2 | null | 2019-06-20 | 2019-07-03 | Rituximab | 02 | null | RITUXIMAB | 100119530 |
| 240000908 | 240011982 | 1.9 | 58.6 | Adjuvant (A) | null | 2020-03-25 | null | N | null | METHOTREXATE | 101326969 |
| 240000922 | 240011986 | 1.44 | 118 | Curative (C) | null | null | null | 02 | null | METHOTREXATE | 100060122 |